In one aspect, the present application discloses compositions of
extracellular vesicles (EVs) comprising
heterologous effector RNAs, such as
antifungal RNAs. In certain embodiments, the
effector RNAs comprise dsRNA, while in other embodiments the
effector RNAs comprise mRNA In certain embodiments, the EVs are
plant EVs, microbial EVs (e.g., bacterial EVs or fungal EVs), or artificial EVs. In particular embodiments, the EVs are
plant EVs and the effector
RNA is mRNA. In other particular embodiments, the EVs are microbial EVs and the effector
RNA is dsRNA. In other aspects, the application discloses microbes that produce
RNA-loaded EVs; methods of treating and / or preventing fungal diseases by applying such microbes and / or RNA-loaded EVs to plants,
plant parts, and / or soil; and methods of producing such RNA-loaded EVs. In certain examples, the
antifungal RNAs may target DCL1 / 2 genes the VDS genes, and / or the tetraspanin (PLS1) genes of a
fungal pathogen such as B. cinerea,
Verticillium dahliae,
Sclerotinia sclerotiorum,
Fusarium oxysporum,
Fusarium graminearum,
Aspergillus niger or even
oomycete pathogens, such as
Phytophthora infestans.